Business
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 wit...
About this update from Viridian Metals Inc
[{"type":"text","content":"Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwalignr { text-align: right; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwdoublebottom { border-bottom: double black 2.25pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadb4 { padding-bottom: 5px }\n.bwpadl0 { padding-left: 0px }\n.bwpadl4 { padding-left: 20px }\n.bwpadl8 { padding-left: 40px }\n.bwpadr0 { padding-right: 0px }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwwidth1 { width: 1% }\n.bwwidth100 { width: 100% }\n.bwwidth13 { width: 13% }\n.bwwidth19 { width: 19% }\n.bwwidth2 { width: 2% }\n.bwwidth3 { width: 3% }\n.bwwidth54 { width: 54% }\n.bwwidth67 { width: 67% }\n \n\n\n\n\n - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway -\n \n\n\n\n - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 -\n \n\n\n\n - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 -\n \n\n\n\n - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 -\n \n\n\n\n - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian’s Board of Directors -\n \n\n\n\n - Strong cash position of $636.6 million as of March 31, 2025, which supports cash runway into the second half of 2027 -\n \n\n\n\n\n Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025.\n \n\n “We continue to execute across the portfolio as we work towards submitting the veligro...